Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma
NCT04892446
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is looking at a new medicine called magrolimab to see if it's safe and works well when given with other cancer medicines. The study is being done on people with a type of cancer called multiple myeloma that has come back or isn't responding to other treatments. They will test the combination of magrolimab with different cancer medicines to find the best dose and to see if it helps people with multiple myeloma.
This study is looking at a new medicine called magrolimab to see if it's safe and works well when given with other cancer medicines. The study is being done on people with a type of cancer called multiple myeloma that has come back or isn't responding to other treatments. They will test the combination of magrolimab with different cancer medicines to find the best dose and to see if it helps people with multiple myeloma.
Third Opinion AI Generated Synopsis
Trial Summary
The primary objective of this study for the Safety Run-in Cohorts is to evaluate the safety and tolerability of magrolimab in combination with other anticancer therapies and to determine the recommended Phase 2 dose (RP2D) of magrolimab in participants with relapsed/refractory multiple myeloma (MM) for the following combinations: magrolimab + daratumumab, magrolimab + pomalidomide + dexamethasone, and magrolimab + bortezomib + dexamethasone. The primary objective of this study for the Dose Expansion Cohorts is to evaluate the efficacy of magrolimab in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma as determined by objective response rate (ORR).
The primary objective of this study for the Safety Run-in Cohorts is to evaluate the safety and tolerability of magrolimab in combination with other anticancer therapies and to determine the recommended Phase 2 dose (RP2D) of magrolimab in participants with relapsed/refractory multiple myeloma (MM) for the following combinations: magrolimab + daratumumab, magrolimab + pomalidomide + dexamethasone, and magrolimab + bortezomib + dexamethasone. The primary objective of this study for the Dose Expansion Cohorts is to evaluate the efficacy of magrolimab in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma as determined by objective response rate (ORR).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
